Utathya Bhadra - WIZBII Utathya Bhadra a publié son profil professionnel sur WIZBII. U B

Utathya Bhadra

46 ans • Port Elizabeth

Résumé

Steriles Technical Development, Troubleshoot & Technology Transfer Specialist for Injectables/Parenterals including biologicals & ophthalmic formulations. Project Manager and Sr Formulation Research Scientist. Cross-functional experience in diff areas such as Dev, Tech transfer, QA, Manufacturing Operations and Reg Affairs. International Tech Transfer Specialist. Generic Drug Product Research & Devlpmnt. 13 years of global work experience with top multinational cos., lived and worked in S Korea, India, South Africa and United Kingdom. Registered Pharmacist and Intl Degree from Univ of London.

Compétences

Steriles/Parenterals Formulation And Tech Transfer ExpertProject Management Using PM Tools Like MS ProjectSteriles Process Validation And TroubleshootingInternational Tech Transfer SpecialistQbDDoERisk AssessmentProcess Capability (CpK) AnalysisPreparation Of Dept SOPsGeneric Drug Development

Expériences

Parenteral & Liquid Products Technical Specialist (Technology Transfer Project Manager)

- MaintenantServices à la personneAs a steriles project manager, coordinated closely with production, supply chain, logistics, analytical development and quality control for successful planning of pilot/trial and validation batch activities. As a steriles technical specialist and project manager, planned and assisted with conversion, optimization, formulation manufacturing and technical troubleshooting and analytical method transfer/validation and trouble shooting of existing and new product ranges of sterile projects (including biological injectable products) and ophthalmic preparations at different stages in the sterile manufacturing pathway and product life-cycle. As a steriles project manager, planned and successfully executed several exhibit batches and complete sterile process validation exercises for several technology transfers projects. Implementation of sterile projects in the factory by evaluating product and process feasibility on the available sterile platform through evaluation of submission documentation and product dossiers and assessing the suitability for its transfer into the receiving site. Identification of risks involved during the course of entire technology transfer process, drawing up formal risk assessment and developing appropriate risk mitigation strategies through implementation of QRM tools, wherever applicable. As a steriles projects technology transfer projects manager and department team lead, prepared, drafted and finalized departmental SOPs for sterile tech transfer projects. Setting up the validation master plan, validation matrix, risk assessment and identification of worst case conditions in consultation with site validation department with due consideration to cGMP validations requirements for sterile projects such as, but not limited to, filter validation, hold time study, media fill validations, cleaning validation and transport validation including container-closure integrity assessments. Analyzing process capability (Cpk) and process performance capability (Ppk) during sterile filling operation using statistical tools depending on machine capability. Provide detailed assessment of primary packing components, prepare, plan and execute stability protocols including leachables study on the finished product. As a formulation research scientist established quality target product profile (QTPP) by identifying critical processing parameters through CMC and CQA review of dossier and cognitively prepared design space by implementation of quality by design (QbD) principles during early phase development. Review of batch manufacturing instruction and preparation of project plan. Well aware of current regulatory guidelines and substantially experienced in the preparation of documents related to common technical document (CTD) and other dossier related documents which were used in actual submissions. Actively involved during site inspection by German Regulatory (BfArM) and experienced in responding to regulatory queries (RTQs) from various Ministry of Health (MoH) post submission. Exposure to project planning tools such as Microsoft Project and statistical data research tools such as Minitab. Successfully completed international technology transfer of sterile projects with invaluable site visit to GSK facility in France, on July 2014. The site now owned by Aspen.

Senior Research Scientist

- Services à la personneEstablishing platforms for developing non-infringing techniques of generic drug development for sterile dosage forms and also for conventional and modified release solid orals primarily for regulated markets. Successfully executed several exhibit batches for conventional and modified release solid orals and achieved pivotal bioequivalence through precise interpretation of in-vitro dissolution and in-vitro/in-vivo correlation and relationship using statistical tools, wherever necessary. Awarded with “core value performer” for the month of March 2009 by Daewoong for excellence in product research and development and successful submission of four projects. Successful development and launching of generic Olanzapine tablets in South Korean market. Successful formulation and development of incrementally modified (equivalent to NDA’s 505b2) Imatinib Mesylate Tablets, which passed Phase I comparative pharmacokinetic human clinical study.

Research Associate – (Senior Executive)

- Services à la personneSuccessfully executed several exhibit batches for conventional and modified release solid orals and achieved pivotal bioequivalence through precise interpretation of in-vitro dissolution and in-vitro/in-vivo correlation and relationship using statistical tools, wherever necessary. Successfully filed several Para IV/ANDA and European submissions. Co-researcher in the generic product development of Ibandronate Sodium tablets which received first-to-file tentative ANDA marketing approval from USFDA on January 6, 2010, following its approval in Mar 19, 2012.

Research Associate

- Services à la personneCo-researcher in the generic product development of Divalproex Sodium extended release tablets which received ANDA marketing approval on February 10, 2009

Research & Development Officer

- Services à la personne

Formations

The School Of Pharmacy, University Of London

2002 - 2003 London, UK, LondonServices à la personne

Langues parlées

  • Anglais

    Langue maternelle

  • Hindi

    Langue maternelle

  • Bengali

    Langue maternelle

  • Coréen

    Intermédiaire

Ma présence sur internet

Faire de chaque avenir une réussite.
  • Annuaire emplois
  • Annuaire entreprises
  • Événements